Highlights from the Big Pharma Report posted on AOL's Motley Fool Pfizer Board.
BigKNY3
__________________________
Big Pharma Report- 2/14/98
Week
After four consecutive weeks of gains, Big Pharma finally gave a little back (-0.1%) as compared to gains for the record breaking Dow (+2.7%), S&P (+0.8%) and the NAStie (+0.9%). Three of the "Healthy 13" set all-time highs; PNU (40.88), ABT (74.63) and JNJ (70.00)
PFE (+3.4%) led Big Pharma based on good news on Lipitor (see below) and anticipation of Viagra and even a possible Cox-2 marketing partneship with Searle. After announcing a 2-1 split on Friday, ABT gained 3.1%.
LLY (-4.6%) was the clear laggard with concerns over somewhat lower than expected Evista new Rxs. AHP (-3.2%) continues to demerge. WLA (-2.8%) was hit by new Rezulin rumors.
February 1998
Big Pharma (+1.3%) trails the Dow (+2.7%) and is outgaining the S&P (+0.8%) and the NASTie (+0.9%). Potential mergers GLX (+17.3%) and SBH (+7.7%) are the Feb leaders. Laggard AMGN (+7.4%) is trying to get back to even.
Less than Febulous are.... left at the altar AHP (-7.9%) and the surprise disappointment of the year (and greatest Big Pharma buy opportunity) LLY (-6.3%).
YTD 1998
Big Pharma (+12.1%) continues to outpace the record Dow (+5.8%), the record S&P (+5.2%), the gaining NAStie (+8.9%) and the flat 0.81% gain for the Motley Fool portfolio.
For the first time in Big Pharma Report history, SBH (+32.2%) has taken the YTD lead, followed by its potential merger GLX (+31.9%), WLA (+20.1%), and SGP (+18.2%).
Based on its strong week, PFE has gained 12.2% and is now ranked #7 in Big Pharma.
Despite the launch of Evista, LLY is down 6.3%. Biotechy AMGN (-0.8%) has almost pulled even for the year.
Big Pharma News You Can Use (BigKNY3 Comments)
-The CEO of Astra has said that he hopes the proposed GLX/SBH merger does not trigger a wave of mergers in Big Pharma. " It has shown that it is difficult to maintain good profitablitity in merged companies."
-Lipitor is still flying. Most recent market share is #1 32.6%. Estimated 1998 sales could surpass $2.0 billion.( PFE Lipitor's agreement could go down as the best licensing deal in the history of Big Pharma.)
-LLY slipped on mild disappointment in Evista Rxs. Smith and Barney "The Evista Rxs have been good, but not spectacular." 12% off its high, LLY (last year's #2) should be considered a Buy."
-WLA was hit by another Rezulin rumor of labeling change on Thursday. (Stock manipulation never seems to end.)
-Trovan Ltd, a UK company, has initiated legal action against PFE for trademark infringement concerning PFE's new product.( Funny, I don't think Trovan. Ltd sounds anything like Viagra.)
-On Wednesday, Southeast Research lowered its rating of PFE to hold due to valuation.( Never heard of Southeast, current Zachs PFE ratings: Strong Buy:14, Moderate Buy: 9, Holds: 9, sells:0.)
ED News You Can Use (BigKNY3 Comments)
-NexMed has announced that they have completed Phase I clinical studies of a topical alprostadil cream to treat ED
-V Day Countdown: -45 Days
|
